We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image
  • Published On : Nov 2017
  • Code : CMI1054
  • Pages :106
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Tapentadol - Become Pain Free!

Tapentadol is an opioid analgesic, indicated for severe pain management, on a daily or around the clock need for treatment and long-term opioid treatment, for which alternative treatment options are inadequate. Tapentadol is also indicated for neuropathic pain associated with diabetic peripheral neuropathy. It is widely used for management of acute, chronic, and cancer related pain among patients and is available legally on prescription. Nucynta ER is the first and only FDA-approved long-acting opioid analgesic designed to control both, nociceptive pain and neuropathic pain associated with diabetic peripheral neuropathy. Nucynta is available as Palexia outside the U.S. territory. Nucynta ER is contraindicated for patients suffering from significant respiratory depression, known or suspected gastrointestinal obstruction, acute or severe bronchial asthma or hypercarbia, including paralytic ileus, concurrent use of monoamine oxidase inhibitors (MAOIs), and Hypersensitivity (e.g. anaphylaxis, angioedema) to tapentadol or to any other ingredients of the product or use of MAOIs within a period of 14 days.

Rising incidence of cancer and diabetic neuropathy in the Middle East is expected to fuel growth of the Middle East tapentadol market

According to data published in World Journal of Diabetes in 2016, the Middle Eastern and North African regions are estimated to have the second-highest rate of diabetes in the world, in turn, increasing prevalence of neuropathic pain. In Arab World, the prevalence of diabetes is projected to increase to 96.2% by 2035, as estimated by World Journal of Diabetes in 2016. Furthermore, the World Health Organization (WHO) estimated that in the Eastern Mediterranean region, including Middle East, recorded 555,318 new cases of cancer in 2012, which is projected to rise to 961,098 by 2030. Thus determining that the Eastern Mediterranean region is expected to have the highest relative increase of cancer cases among all regions in the world. According to Journal of Taibah University Medical Sciences, 2016, the number of people suffering from diabetic neuropathic pain in countries of the Middle East were as follows:

Tapentadol Market

To learn more about this report, request a free sample copy

The Middle East tapentadol market was valued at US$ 0.82 million in 2016 and is expected to witness a robust CAGR of 6.1% over the forecast period (2017-2025).

Figure 1. Tapentadol related important events since discovery

Tapentadol Market

To learn more about this report, request a free sample copy

Source: Coherent Market Insights Analysis (2017)

Absence of gold standard opioid therapy for neuropathic pain other than tapentadol is expected to fuel the Middle East tapentadol market growth

Neuropathic pain is caused by a dysfunction of or lesion to the central or peripheral nervous system and it is chronic in nature with a complex pathophysiology. NUCYNTA ER (tapentadol) is used in the treatment of neuropathic pain, if the pain is severe enough to require tapentadol daily, whereas it is also used in long-term opioid treatment for which alternative treatment options are inadequate. There is low quality evidence that the oral tramadol has any important beneficial effect on pain for people suffering from severe or moderate neuropathic pain, whereas the main indication of tapentadol is to treat the diabetic neuropathic pain. This proves that other opioids such as fentanyl, oxycodone, tramadol, and oxymorphone are not as effective as tapentadol in the treatment of neuropathic pain.

The U.S. Food & Drug Administration (FDA) tapentadol approval timeline

tapentadol

To learn more about this report, request a free sample copy

Major players operating in the tapentadol market include Depomed, Inc., Janssen Pharmaceutical, Inc., Grünenthal, and Allergan Plc.

Frequently Asked Questions

The Middle East tapentadol market is estimated to surpass US$ 1.46 Million by 2025.

Major players operating in the Middle East tapentadol market include Depomed, Inc., Janssen Pharmaceutical, Inc., Grünenthal, and Allergan Plc.

Rising prevalence of pain-associated diseases such as cancer and diabetic neuropathy is one of the major factors that is expected to propel growth of the market over the forecast period.

The Middle East tapentadol market is estimated to exhibit a CAGR of 6.1% over the forecast period.

The Middle East tapentadol market was valued at US$ 0.86 Million in 2016 and is estimated to exhibit a CAGR of 6.1% over the forecast period (2017-2025).

Rising prevalence of pain-associated diseases such as cancer and diabetic neuropathy in the region and unavailability of effective alternate therapy for management of neuropathic pain are some of the factors influencing the adoption of tapentadol in the Middle East.

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount
Logo

Reliability and Reputation

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Reliability and Reputation

27001:2022

Reliability and Reputation

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo